Shereen Chang, MD
Neurology · Cedar Rapids, IANPI 1508917857
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,668 of the $2,046 with a category attached, or 81.5%. 29 manufacturers reported payments, led by AbbVie at 31.1% of the total.
Across 110 payments — averaging $18.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$636
- Pfizer$522
- Biogen$80
- Ipsen Biopharmaceuticals, Inc$78
- Abbott$69
- Amgen$67
- plus $594 from 23 others
What the payments were for
- Speaking & faculty fees$191%
- Travel & lodging$35918%
- Food & beverage$1,66882%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 20 | $636 |
| Pfizer | 47 | $522 |
| Biogen | 4 | $80 |
| Ipsen Biopharmaceuticals, Inc | 3 | $78 |
| Abbott | 2 | $69 |
| Amgen | 3 | $67 |
| Lilly USA, LLC | 4 | $59 |
| Johnson & Johnson | 2 | $53 |
| AstraZeneca | 2 | $40 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $39 |
| Genentech USA, Inc. | 2 | $38 |
| Lundbeck LLC | 2 | $36 |
| UCB, Inc. | 1 | $28 |
| Greenwich Biosciences, Inc. | 1 | $24 |
| Kyowa Kirin, Inc. | 1 | $24 |
| Sunovion Pharmaceuticals Inc. | 1 | $23 |
| GE HealthCare | 1 | $22 |
| Resmed Corp | 1 | $21 |
| Supernus Pharmaceuticals, Inc. | 1 | $21 |
| Argenx US, Inc. | 1 | $21 |
| TG Therapeutics, Inc. | 1 | $20 |
| Jazz Pharmaceuticals Inc. | 1 | $19 |
| Acorda Therapeutics, Inc | 1 | $19 |
| Novartis | 1 | $18 |
| Tanabe Pharma America, Inc. | 1 | $16 |
| Bristol Myers Squibb | 1 | $15 |
| Axsome Therapeutics, Inc. | 1 | $15 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $12 |
| Livanova USA, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BOTOX$137
How this compares
$2,046 in reported general payments places this provider in the 70th percentile of 132 neurology providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NamzaricMemantine Hcl/Donepezil Hcl | 35 | $21,643 |
| Emgality PenGalcanezumab-Gnlm | 24 | $21,595 |
| UbrelvyUbrogepant | 11 | $11,008 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 223 | $9,582 |
| Carbamazepine | 88 | $3,592 |
| FingolimodFingolimod Hcl | 12 | $2,568 |
| Levetiracetam | 97 | $2,406 |
| Carbidopa-Levodopa ErCarbidopa/Levodopa | 30 | $2,326 |
| Primidone | 76 | $1,482 |
| Gabapentin | 49 | $1,079 |
| Propranolol Hcl | 68 | $1,035 |
| Ropinirole Hcl | 23 | $723 |
| Lacosamide | 14 | $464 |
| Lamotrigine | 35 | $447 |
| Pregabalin | 25 | $398 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieNamzaric, Ubrelvy | $636 | $32,65146 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 132 neurology providers in Iowa.
Other neurology in Cedar Rapids
- Winthrop RiskCedar Rapids$136K
- Scott GeislerCedar Rapids$87K
- Robert StruthersCedar Rapids$2K
- Thomas RogersCedar Rapids$2K
- Laurence KrainCedar Rapids$2K
- Stephanie JacksonCedar Rapids$852
- Bruce HughesDes Moines$1.8M
- Michael JacobyDes Moines$243K
- Lynn RankinDes Moines$181K
- Wendy ZadehDes Moines$134K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.